Peptide · Fact sheet

GHK-Cu

Also known as copper tripeptide-1 · copper peptide GHK-Cu

GHK-Cu is a copper-binding tripeptide studied in skin, wound, and hair biology. It is not an FDA-approved drug for wound healing, hair loss, anti-aging, or systemic use, and evidence depends heavily on formulation and route.

Not FDA approvedMostly animal or lab research

What is GHK-Cu?

GHK-Cu is a complex of the three-amino-acid peptide glycyl-L-histidyl-L-lysine with copper.

A topical cosmetic ingredient, an experimental wound product, and an injected compounded product are different exposures with different evidence and risks.

Benefits & claims

Laboratory and animal studies report effects on collagen, extracellular matrix, inflammation, and tissue-repair signaling.

It appears in skin-care and hair-growth marketing, where evidence for an ingredient is often stretched into claims about a specific finished product or systemic therapy.

What the evidence supports

  • Animal wound models report increased collagen and extracellular-matrix accumulation.
  • Small cosmetic studies and ingredient research suggest possible skin effects, but results are formulation-specific and not equivalent to an approved medical treatment.
Research areas
  • Collagen and extracellular-matrix signaling
  • Wound repair in animal models
  • Skin appearance and photoaging
  • Hair-follicle biology
  • Topical skin and wound applications
  • Hair-growth and follicle biology
  • Tissue-repair signaling

Dosage & frequency

No established human regimen

Topical GHK-Cu cosmetic evidence does not establish an injectable repair or longevity regimen. No FDA-approved human injectable GHK-Cu dose exists.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Topical cosmetic formulations and systemic injection are different routes with different evidence.

Interactions & precautions

  • Topical cosmetic research does not establish systemic drug interactions for injected GHK-Cu.

What is still unresolved

  • Injectable exposure, dosing, repeated-use safety, and drug interactions remain unestablished.

Side effects & risks

  • FDA identifies potential immune reactions, aggregation, and peptide-related impurity concerns for compounded injectable GHK-Cu.
  • Human systemic safety data are limited, and cosmetic tolerability does not establish safety by another route.
  • Copper exposure, formulation ingredients, contamination, and product mislabeling can change risk.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Mostly animal or lab research

Much of the mechanistic and wound-healing evidence comes from cells or animals. Limited cosmetic research cannot establish broad medical, hair-growth, or systemic anti-aging claims.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Skin: reported experiences

Mixed account · personal report

Perceived hair and skin changes with a recurring rash

An author described darker-looking hair, improved skin appearance and faster nail growth over repeated periods of use, but also a localized rash. A follow-up described the cosmetic changes eventually returning toward baseline.

Reported use in this account

Product
Product described as GHK-Cu
Amount
2.5–5 mg per day in the author's described experiences
Frequency
Daily
Route
Injection; type not stated
Duration
Periods up to six months

Photographs and laboratory results were not shared. This systemic product account cannot be generalized to topical skincare, and it does not establish rash frequency or hair regrowth.

Read the original account
Mixed account · personal report

Initial breakout, then perceived skin improvement

An author described an initial skin breakout followed by clearer skin, less visible acne scarring and tighter-looking facial skin while also using GHRP-6.

Amount, frequency, route and duration could not be confirmed for this account.

There were no standardized photographs or skin measurements. Formulation, other skincare and product identity are unclear; the community has commercial links.

Read the original account
Negative account · personal report

Itching after adding a copper-peptide skin product

A skincare user reported an itchier face after adding copper peptides to a routine that already contained several other products.

Reported use in this account

Product
Copper-peptide skincare product; exact ingredient/formulation not identified
Amount
Not specified clearly
Frequency
Morning and evening
Route
Topical skincare
Duration
Not specified clearly

Other exposures described: Cleanser, toner, niacin essence, hyaluronic-acid cream and sunscreen; tretinoin had been stopped weeks earlier

The full product formula and cause of irritation were not verified. A topical multi-ingredient experience cannot establish an allergy to GHK-Cu or describe systemic exposure.

Read the skincare account

Approval status

No GHK-Cu drug product is FDA approved for wound healing, hair growth, anti-aging, or systemic use. FDA identifies potential immune and impurity risks for compounded injectable GHK-Cu and limited human safety data.

Preclinical and formulation-specific research

GHK-Cu has cosmetic and wound-healing biology, but no FDA-approved drug product for wound healing, hair growth, anti-aging, or systemic use.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Whether any finished product produces clinically meaningful wound or hair outcomes
  • Long-term topical and systemic safety across formulations
  • Whether laboratory signaling changes translate into visible or functional benefit
  • Quality and identity of unapproved products marketed under the name

Summary

GHK-Cu has cosmetic and wound-research findings. Clinical conclusions depend on the formulation, route and outcome studied.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA: safety risks for selected compounded bulk substances

    FDA's current substance-specific summary of evidence gaps and potential safety risks.

  2. pubmedGHK-Cu wound study in rats

    Animal wound-chamber study showing extracellular-matrix effects; not proof of human clinical benefit.

  3. fdaFDA: 503A bulk-substance status for GHK-Cu

    FDA status document distinguishing non-injectable evaluation from injectable safety concerns.

  4. fdaFDA: understanding the risks of compounded drugs

    FDA overview explaining that compounded drugs are not reviewed before marketing for safety, effectiveness, or quality.

How we assess sources · Suggest a correction